U.S. Initiates Testing of Potential Covid-19 Vaccine

USA: Potential Coronavirus Solution U.S. Initiates Testing of Potential Covid-19 Vaccine

17.03.2020Editor: Ahlam Rais

Testing of the potential covid-19 vaccine – mrna-1273 developed by the National Institutes of Health and biotechnology firm Moderna has started in the USA. If the research proves successful, the company will be able to mass produce the cure only after 12 to 18 months.

The testing of the vaccines on people is essential to determine if it is safe and can fight the coronavirus.
(Source: Deposit Photos)

USA – The U.S. has recently begun testing its potential covid-19 vaccine called mrna-1273 by vaccinating four healthy volunteers in the country. The vaccine has been developed by the National Institutes of Health (NIH) and biotechnology firm Moderna in record time and one of the major factors towards this success was the availability of the virus’ genetic sequence by Chinese scientists.

The testing of the vaccines on people is essential to determine if it is safe and can fight the virus. According to news reports, Dr. Anthony Fauci of the U.S. National Institutes of Health states, “Even if the research goes well, a vaccine would not be available for widespread use for 12 to 18 months.”

With the rise in the number of deaths and people affected by the virus around the world, there are many other companies hurrying to create a potential covid-19 vaccine including Curevac, Inovio Pharmaceuticals, Pfizer and many more.

Unfold for details of your consent

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:46413180)

USA: Potential Coronavirus Solution U.S. Initiates Testing of Potential Covid-19 Vaccine

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Consent to the use of data for promotional purposes